Skip to main content
. 2023 Dec 7;30(4):836–848. doi: 10.1158/1078-0432.CCR-23-2693

Figure 2.

Figure 2. GOF fusions and rearrangements. A, Heatmap of the prevalence of the most frequently rearranged oncogenes in the pan-tumor cohort (cancer types with ≥200 LBx shown). Kinase genes on the left, transcription factors on the right (only genes rearranged in ≥0.5% of any cancer type shown). B, The clonal fraction (VAF/TF) of gene rearrangements considered to be potential pan-tumor biomarkers and which appear in multiple cancer types. Median and interquartile range shown. Cancer types (n ≥ 10 with a rearrangement in the gene) are arranged in order of median VAF/TF. C, In tissue and liquid biopsies from the same patient, the VAF/TF of each rearrangement that was detected in both tissue and liquid (concordant) or in the liquid biopsy only. Tissue/liquid pairs where liquid was collected up to 90 days earlier and up to 2 years later than the tissue specimen were considered. Additional information about this analysis is available in Supplementary Table S6.

GOF fusions and rearrangements. A, Heatmap of the prevalence of the most frequently rearranged oncogenes in the pan-tumor cohort (cancer types with ≥200 LBx shown). Kinase genes on the left, transcription factors on the right (only genes rearranged in ≥0.5% of any cancer type shown). B, The clonal fraction (VAF/TF) of gene rearrangements considered to be potential pan-tumor biomarkers and which appear in multiple cancer types. Median and interquartile range shown. Cancer types (n ≥ 10 with a rearrangement in the gene) are arranged in order of median VAF/TF. C, In tissue and liquid biopsies from the same patient, the VAF/TF of each rearrangement that was detected in both tissue and liquid (concordant) or in the liquid biopsy only. Tissue/liquid pairs where liquid was collected up to 90 days earlier and up to 2 years later than the tissue specimen were considered. Additional information about this analysis is available in Supplementary Table S6.